Oxford BioDynamics Plc OBD
LSE · United Kingdom · Health Technology
GBp 0.1150-0.01 (-4.96%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, quantified by the EpiSwitch® Prostate Cancer Detection (PSE) blood test. In this 10-patient cohort (ages 54–76), mean PSE probability scores decreased from 0.56 (±0.27) at baseline to 0.39 (±0.31) post-therapy—a relative reduction of approximately 31% (paired t-test, p=0.045; Cohen's d=0.69). Eight
Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Oxford Biodynamics PLC (OBD) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This comprehensive report serves as a vital source of data, analysis, and actionable intelligence regarding Oxford Biodynamics' extensive portfolio of pipeline products. It is crafted to enhance decision-making processes and helps in developing robust counter strategies ensuring competitiveness in the biotech industry. Report S
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.